← Back to Search

Children with ADHD group for Attention Deficit Hyperactivity Disorder (ADHD) (ADE Trial)

N/A

Recruiting

Led By Guillaume guillaume.leonard2@usherbrooke.ca, pht., PhD

Research Sponsored by Université de Sherbrooke

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up the outcome measure should be assessed during the visit 2, which should occur in 3-4 months. data should be reported within the following 6 months.

Awards & highlights

ADE Trial Summary

This trial aims to better understand the role of expectations in children with ADHD in a medical (pain) and school (attention abilities) context by modulating children's expectations and measuring brain activity.

Eligible Conditions

Attention Deficit Hyperactivity Disorder (ADHD)
Placebo Effect
Nocebo Effect
Pain

ADE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ the outcome measure should be assessed during the visit 2, which should occur in 3-4 months. data should be reported within the following 6 months.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~the outcome measure should be assessed during the visit 2, which should occur in 3-4 months. data should be reported within the following 6 months.

This trial's timeline: 3 weeks for screening, Varies for treatment, and the outcome measure should be assessed during the visit 2, which should occur in 3-4 months. data should be reported within the following 6 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Placebo and nocebo effect on attention abilities

Placebo and nocebo effect on pain

Secondary outcome measures

ADHD symptoms

Anxiety traits

Heart rate measures

+9 more

ADE Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Children with ADHD groupExperimental Treatment1 Intervention

The same protocol is used for both groups

Group II: Children with no ADHD groupActive Control1 Intervention

The same protocol is used for both groups

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Université de SherbrookeLead Sponsor

292 Previous Clinical Trials

69,397 Total Patients Enrolled

1 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)

60 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Guillaume guillaume.leonard2@usherbrooke.ca, pht., PhDPrincipal InvestigatorUniversité de Sherbrooke

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still room for participants in this clinical study?

"Currently, this clinical trial is recruiting participants as indicated by data found on clinicaltrials.gov. This research project was initially published on February 17th 2021 and was most recently revised on July 26th 2022."

Answered by AI

Is this medical research accepting senior participants?

"This clinical trial seeks out patients aged 8 to 9 years old. Altogether, 412 studies for minors and 895 trials targeting the elderly exist on this platform."

Answered by AI

May I be included as a study participant in this experiment?

"Qualified participants of this trial must have pain as a symptom and be aged 8 to 9. A total of 44 individuals are being recruited for the study."

Answered by AI

What is the maximum number of participants that will be enrolled in this clinical trial?

"Affirmative. According to clinicaltrials.gov, this research opportunity is open for enrollment with a start date of February 17th 2021 and an update on July 26th 2022. At the moment, 44 participants are sought from a single medical centre."

Answered by AI

What outcomes is this trial anticipating?

"This clinical trial's primary outcome is tracking changes in pain sensation following placebo and nocebo administration. Secondary outcomes include assessment of DLPFC neural activity via functional MRI, Pain Catastrophizing Scale for Children scores collected in French, and inhibitory mechanisms evaluated with transcranial magnetic stimulation (TMS). Results will be reported within 6 months."

Answered by AI

Recent research and studies

PainJournal

The Validation of Visual Analogue Scales as Ratio Scale Measures for Chronic and Experimental Pain

Price, Donald D., Patricia A. McGrath, Amir Rafii, and Barbara Buckingham. 1983. “The Validation of Visual Analogue Scales as Ratio Scale Measures for Chronic and Experimental Pain”. Pain. Ovid Technologies (Wolters Kluwer Health). doi:10.1016/0304-3959(83)90126-4.

Current Opinion in NeurobiologyJournal

Brain Development in ADHD

Friedman, Lisa A, and Judith L Rapoport. 2015. “Brain Development in ADHD”. Current Opinion in Neurobiology. Elsevier BV. doi:10.1016/j.conb.2014.11.007.

The Journal of NeuroscienceJournal

Conscious Expectation and Unconscious Conditioning in Analgesic, Motor, and Hormonal Placebo/nocebo Responses

Benedetti, Fabrizio, Antonella Pollo, Leonardo Lopiano, Michele Lanotte, Sergio Vighetti, and Innocenzo Rainero. 2003. “Conscious Expectation and Unconscious Conditioning in Analgesic, Motor, and Hormonal Placebo/nocebo Responses”. The Journal of Neuroscience. Society for Neuroscience. doi:10.1523/jneurosci.23-10-04315.2003.

American Journal of PsychiatryJournal